Orgenesis teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs OMPULs are multi-purpose mobile autonomous good manufacturing practice facilities intended to develop, optimize, and manufacture cell and gene therapies at the point of use The latest collaboration follows a recent joint venture agreement between Orgenesis and Cure Therapeutics to target cancer and infectious diseases Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced Monday it has signed a collaboration agreement with Dong-a University Hospital in South Korea and Cure Therapeutics Inc to utilize Orgenesis Mobile Processing Units and Labs (OMPULs).